Androgens and prostate cancer risk: A prospective study

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

BACKGROUND. Androgens have been implicated in prostate tumorigenesis, but prospective studies have overall reported no association between circulating levels of androgens and risk of prostate cancer. However, some recent studies have shown that a high level of testosterone increase the risk of non-aggressive tumors but is associated with a decreased risk of aggressive tumors. METHODS. We prospectively measured plasma levels of total testosterone, androstanediol glucuronide (A-diol-g) and sex hormone binding globuline (SHBG) and calculated estimated levels of free testosterone, in a nested case-control study of 392 cases and 392 matched controls. RESULTS. None of the studied hormones were significantly associated with prostate cancer risk in the full study group or in subgroups according to tumor aggressiveness. Odds ratios in the full study group, for top versus bottom quartile, was for total testosterone 1.25 (95% CI = 0.79-2.00; Ptrend = 0.51); free testosterone, 1.31 (95% CI = 0.82-2.07; Ptrend = 0.35); A-diol-g, 0.88 (95% CI = 0.59-1.33; P trend = 0.77); and for SHBG, 1.01 (95% CI = 0.64-1.58; P trend = 0.94). CONCLUSIONS. We found no significant associations between androgen levels and risk of prostate cancer in this population-based, non-screened cohort.

Detaljer

Författare
  • Sara Wirén
  • Tanja Stocks
  • Sabina Rinaldi
  • Göran Hallmans
  • Anders Bergh
  • Ulf Håkan Stenman
  • Rudolf Kaaks
  • Pär Stattin
Externa organisationer
  • Umeå University
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Urologi och njurmedicin

Nyckelord

Originalspråkengelska
Sidor (från-till)1230-1237
Antal sidor8
TidskriftProstate
Volym67
Utgåva nummer11
StatusPublished - 2007 aug 1
PublikationskategoriForskning
Peer review utfördJa
Externt publiceradJa